original ) (raw )Evaluation of the efficacy and safety of home treatment with the recombinant human C1-inhibitor in hereditary angioedema resulting from C1-inhibitor deficiency
Henriette Farkas
International Immunopharmacology
View PDFchevron_right
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor
Robert Nathan
The New England journal of medicine, 2017
View PDFchevron_right
Safety and Efficacy of Prophylactic Nanofiltered C1-inhibitor in Hereditary Angioedema
Ira Kalfus
2012
View PDFchevron_right
Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency
Goda Choi
Journal of Allergy and Clinical Immunology, 2006
View PDFchevron_right
Long-Term Prophylaxis of Hereditary Angioedema with a Pasteurized C1 Inhibitor Concentrate
Marcus Maurer
International Archives of Allergy and Immunology, 2011
View PDFchevron_right
C1 Inhibitor Activity and Angioedema Attacks in Patients with Hereditary Angioedema
Joseph Chiao
The Journal of Allergy and Clinical Immunology: In Practice, 2019
View PDFchevron_right
Recombinant human C1-inhibitor in the treatment of acute angioedema attacks
Goda Choi
2007
View PDFchevron_right
Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group
I. Boccon-Gibod , Henriette Farkas
Allergy, 2012
View PDFchevron_right
Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study
Mauro Cancian , Enrico Cillari
Clinical & Experimental Allergy, 2012
View PDFchevron_right
Efficacy and Safety of an Intravenous C1-Inhibitor Concentrate for Long-Term Prophylaxis in Hereditary angioedema
Ralph Shapiro
Allergy & Rhinology, 2017
View PDFchevron_right
Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema
glenne gunther
New England Journal of Medicine, 2010
View PDFchevron_right
Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema
Laurel Omert
Nursing Open
View PDFchevron_right
Diagnostic and therapeutic management of hereditary angioedema due to C1-inhibitor deficiency: the Italian experience
valeia bafunno
Current opinion in allergy and clinical immunology, 2015
View PDFchevron_right
Recombinant Human-C1 Inhibitor Is Effective and Safe for Repeat Hereditary Angioedema Attacks
Avner Reshef
The Journal of Allergy and Clinical Immunology: In Practice, 2015
View PDFchevron_right
Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data
Ralph Shapiro
The journal of allergy and clinical immunology. In practice, 2016
View PDFchevron_right
Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema
Jonathan Bernstein
The journal of allergy and clinical immunology. In practice
View PDFchevron_right
Hereditary Angioedema Due to C1-Inhibitor Deficiency in Romania: First National Study, Diagnostic and Treatment Challenges
Valentin Nadasan
Iranian Journal of Immunology, 2020
View PDFchevron_right
Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema
Avner Reshef
Pediatric Allergy Immunology and Pulmonology, 2020
View PDFchevron_right
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress
Sonia Caccia
Trends in Molecular Medicine, 2009
View PDFchevron_right
Guideline: Hereditary angioedema due to C1 inhibitor deficiency
Marcus Maurer
Allergo Journal International, 2019
View PDFchevron_right
Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks
Moshe Fridman
Allergy, Asthma & Clinical Immunology, 2019
View PDFchevron_right
Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert(®)) in a French cohort
Anne Gompel
European journal of dermatology : EJD, 2017
View PDFchevron_right
Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency
Lilian Varga
Clinical, Cosmetic and Investigational Dermatology, 2011
View PDFchevron_right
Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency
andrea zanichelli
Allergy, 2009
View PDFchevron_right
The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency
Lilian Varga
Orphanet Journal of Rare Diseases, 2014
View PDFchevron_right
Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema
Hilary Longhurst
Clinical & Experimental Allergy
View PDFchevron_right
Treatment of Patients with Hereditary Angioedema with Normal C1 Inhibitor: Evaluation of 295 Patients
Eliana Toledo
Journal of Allergy and Clinical Immunology, 2019
View PDFchevron_right
Acquired Angioedema with C1 Inhibitor Deficiency: Occurrence, Clinical Features, and Management: A Nationwide Retrospective Study in the Czech Republic Patients
Radana Zachová
International Archives of Allergy and Immunology, 2021
View PDFchevron_right
Prophylactic treatment with plasma-derived C1 inhibitor in idiopathic non-histaminergic angioedema
Angelica Petraroli
Pediatric Allergy and Immunology, 2016
View PDFchevron_right